Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. Idorsia Ltd
  6. News
  7. Übersicht
    IDIA   CH0363463438

IDORSIA LTD

(A2DTEB)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News

GlobeNewswire/Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company

28.07.2021 | 07:00

Ad hoc announcement pursuant to Art. 53 LR

NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS. This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Japan, Australia or South Africa

   -- Idorsia launches the offering of approx. CHF 600 million convertible 
      bonds 

Allschwil, Switzerland -- July 28, 2021

Idorsia Ltd (SIX: IDIA, "Idorsia") today announced the launch of approx. CHF 600 million senior unsecured convertible bonds (the "Bonds") due 2028 convertible into shares of Idorsia (the "Shares"). The net proceeds from the offering will be used to support commercial product launches in several key markets in 2022 (pending regulatory approval) and to fund the further development of the company's advancing late-stage pipeline https://www.idorsia.com/about-idorsia/idorsia-today/our-pipeline .

Idorsia's main shareholders, Jean-Paul and Martine Clozel, are fully committed to Idorsia over the long-term and as such indicated to the Issuer their intention to purchase the Bonds at the bookbuilding price pro rata to their current shareholding of 29% in Idorsia.

Idorsia, as well as Jean-Paul and Martine Clozel, have agreed to a 90-day lock-up period after the issuance of the Bonds, subject to waiver by the Joint Bookrunners and customary exceptions.

Jean-Paul Clozel, MD and Chief Executive Officer, commented:

"Based on the ongoing discussions with regulatory authorities, we are confident that we will be launching products in 2022. These products have the potential to take us to profitability, as set out as a mid-term strategic priority. With additional late-stage assets delivering results in the near-term, we are well positioned to further leverage the investment we are making in our global infrastructure. This puts us well on-track to fulfilling our ambition to become a leading biopharmaceutical company, based on innovation."

Issuance of senior unsecured convertible bonds

The Bonds will have a maturity of 7 years and will be convertible into newly issued registered shares of Idorsia, sourced from the existing listed conditional share capital, on or after September 14, 2021. The Bonds will be offered with a coupon between 1.625% and 2.125%, payable annually in arrears, and a conversion premium between 40% and 45% above the volume weighted average price of the Shares between launch and close of trading on July 28, 2021 The Bonds will be issued and, unless previously converted or repurchased and cancelled, redeemed at 100% of their principal amount with a denomination of CHF 200,000 per Bond on the stated maturity date, which is expected to be on August 04, 2028. Idorsia will be entitled to redeem the Bonds at their principal amount (plus accrued interest) in accordance with the terms and conditions of the Bonds at any time (i) on or after August 25, 2025, if the price of an Idorsia share is equal to or exceeds 150% of the then prevailing conversion price over a certain period or (ii) if less than 15% of the aggregate principal amount of the Bonds originally issued remains outstanding. Holders will be entitled to require an early redemption of the Bonds at their principal amount (plus accrued interest) in accordance with the terms and conditions of the Bonds on August 04, 2026. Holders of the Bonds who convert their Bonds will receive Idorsia shares with a par value of CHF 0.05 per share.

The interest on the Bonds will be subject to Swiss withholding tax (which is currently at a rate of 35%).

The offering of the Bonds will be conducted as a private placement in and outside of Switzerland. The advance subscription rights of shareholders have been excluded. The Bonds will be offered to investors outside the US in reliance on Regulation S under the US Securities Act of 1933, as amended, and in compliance with the laws and regulations applicable in every country where the offering takes place. Manufacturer target market (MIFID II product governance) for the Bonds is eligible counterparties and professional clients only (all distribution channels). No Packaged Retail and Insurance-based Investment Products Regulations (PRIIP) key information document (KID) has been prepared as the offering is not available to retail in the European Economic Area (EEA).

The Bonds are expected to price later today. The settlement date of the Bonds is expected to be on or around August 4, 2021. At settlement, the Bonds will not be admitted to trading or listed on the SIX Swiss Exchange or any other Swiss trading venue. Application for the listing and trading of the Bonds according to the Standard for Bonds of SIX Swiss Exchange may be made at a later stage.

Notes to the editor

About Idorsia

Idorsia Ltd is reaching out for more -- We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland -- a European biotech-hub -- Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet -- the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,000 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 58 844 10 10

investor.relations@idorsia.com -- media.relations@idorsia.com -- www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF IDORSIA LTD (THE "ISSUER").

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SHARES, CONVERTIBLE BONDS OR OTHER SECURITIES IN THE ISSUER (COLLECTIVELY, THE "SECURITIES") TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE ISSUER ARE NOT BEING PUBLICLY OFFERED. IN PARTICULAR, THE SECURITIES OF THE ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US SECURITIES ACT OF 1933 (THE "SECURITIES ACT") OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA OR JAPAN.

(MORE TO FOLLOW) Dow Jones Newswires

July 28, 2021 01:00 ET (05:00 GMT)

Alle Nachrichten zu IDORSIA LTD
20.09.Santhera sichert Finanzierung von 45 Millionen - Aktien im Rückwärtsgang
AW
20.09.Santhera sichert Finanzierung von 45 Mio und legt erste Halbjahreszahlen vor
AW
16.09.Aktien Schweiz: SMI behauptet sich über 12'000 Punkten
AW
16.09.Aktien Schweiz Eröffnung: SMI gelingt Rückkehr über 12'000-Punkte-Marke
AW
16.09.Aktien Schweiz Vorbörse: SMI dürfte Rückkehr über 12'000-Punkte-Marke gelingen
AW
03.09.Aktien Schweiz Schluss: Schwache US-Jobdaten belasten leicht
AW
03.09.Aktien Schweiz: Leicht tiefere Kurse vor den US-Arbeitsmarktdaten
AW
03.09.Aktien Schweiz Eröffnung: Etwas leichter - Warten auf US-Jobdaten
AW
30.07.Morning Briefing - Markt Schweiz
AW
29.07.JEAN-PAUL CLOZEL : Idorsia-Grossaktionäre Clozels werden von Angebotspflicht nach Anleihe ..
AW
Weitere Nachrichten
News auf Englisch zu IDORSIA LTD
20.09.PRESS RELEASE : Santhera Secures CHF 45 Million in Funding and Announces Preliminary First..
DJ
06.08.Antares pharma reports second quarter 2021 financial and operating resultsewing
AQ
29.07.IDORSIA : Application of Jean-Paul and Martine Clozel regarding the exemption from the off..
PU
29.07.PRESS RELEASE : Application of Jean-Paul and -2-
DJ
29.07.PRESS RELEASE : Application of Jean-Paul and Martine Clozel regarding the exemption from t..
DJ
29.07.IDORSIA : Places $660 Million Convertible Bonds Due 2028; Shares Down 10%
MT
28.07.IDORSIA : announces the reference share price and the initial conversion price of converti..
AQ
28.07.PRESS RELEASE : Idorsia announces the reference -2-
DJ
28.07.PRESS RELEASE : Idorsia announces the reference share price and the initial conversion pri..
DJ
28.07.IDORSIA : successfully completes the offering of convertible bonds, securing funding to de..
PU
Weitere Nachrichten auf Englisch
Analystenempfehlungen zu IDORSIA LTD
Mehr Empfehlungen
Finanzkennziffern
Umsatz 2021 31,7 Mio 34,2 Mio 29,2 Mio
Nettoergebnis 2021 -633 Mio -684 Mio -584 Mio
Nettoverschuldung 2021 378 Mio 408 Mio 348 Mio
KGV 2021 -5,73x
Dividendenrendite 2021 -
Marktkapitalisierung 3 725 Mio 4 025 Mio 3 435 Mio
Marktkap. / Umsatz 2021 130x
Marktkap. / Umsatz 2022 49,1x
Mitarbeiterzahl 650
Streubesitz 63,5%
Chart IDORSIA LTD
Dauer : Zeitraum :
Idorsia Ltd : Chartanalyse Idorsia Ltd | MarketScreener
Vollbild-Chart
Chartanalyse-Trends IDORSIA LTD
KurzfristigMittelfristigLangfristig
TrendsNeutralFallendFallend
Ergebnisentwicklung
Analystenschätzung
Verkaufen
Kaufen
Durchschnittl. Empfehlung AUFSTOCKEN
Anzahl Analysten 11
Letzter Schlusskurs 22,26 CHF
Mittleres Kursziel 31,13 CHF
Abstand / Durchschnittliches Kursziel 39,8%
Verlauf des Gewinns je Aktie
Vorstände und Aufsichtsräte
Jean-Paul Clozel Chief Executive Officer & Director
André C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Branche und Wettbewerber
01.01.Wert (M$)
IDORSIA LTD-12.77%4 032
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS33.82%67 216
VERTEX PHARMACEUTICALS-21.68%48 018